ProQR Therapeutics N.V. (PRQR) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PRQR currently has 102M outstanding shares. with significant dilution risk as 153M authorized shares could dilute existing holders by 150.7%. The company has not diluted shareholders through share issuances in the past 2 years, which is positive for existing holders.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 13, 2025 |
F-3 filing: This F-3 filing relates to the proposed resale or other disposition of up to 3,523,538 ordinary shares by the selling shareholder. |
100M | 150M |
| Mar 13, 2025 |
20-F filing | 105.2M shares outstanding |
110M | 150M |
| Sep 30, 2024 |
F-3 filing: The company intends to offer ordinary shares, warrants and/or units with an aggregate public offering price of up to $300,000,000 to primarily fund research and development and clinical development, with the remainder for working capital, capital expenditures and other general corporate purposes. |
120M | 130M |
| Mar 13, 2024 |
20-F filing | 81.4M shares outstanding |
81M | 1.5M |
| Mar 29, 2023 |
20-F filing | 80.8M shares outstanding |
81M | 2M |
| Mar 29, 2023 |
F-3 filing: This F-3 filing relates to the resale of up to 13,371,562 ordinary shares by selling shareholders. |
67M | 15M |
| Apr 29, 2022 |
20-F filing | 71.3M shares outstanding |
71M | 0 |
| Mar 01, 2022 |
F-3 filing: Resale of ordinary shares issuable pursuant to convertible notes and warrants by selling shareholders. |
71M | 0 |
| Nov 04, 2021 |
F-3 filing: This is an F-3 filing for the resale of up to 3,989,976 ordinary shares by selling shareholders. |
71M | 0 |
| Nov 04, 2021 |
F-3 filing: ProQR Therapeutics N.V. is offering ordinary shares, warrants, and/or units from time to time, with an aggregate public offering price of up to $300,000,000; shares outstanding as of September 30, 2021 was 71,154,571. |
71M | 0 |
| Mar 24, 2021 |
20-F filing | 54.1M shares outstanding |
54M | 0 |
| Sep 11, 2020 |
F-3 filing: This F-3 filing relates to the resale of up to 2,857,254 ordinary shares issuable upon conversion of convertible notes and exercise of warrants by selling shareholders. |
50M | 2.5M |
| Mar 31, 2020 |
20-F filing | 49.7M shares outstanding |
50M | 0 |